Open for inclusion

A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors”

Cancer type: Solide tumores

Phase: I/II

Principal Investigator: Bono Petri

Country: FI

Keywords: Finland, Helsinki,

Status: Open for inclusion

Link to